Pfizer's Story: A Guidance Cut, a Comeback, Then Two Shocks at Once

The story

Late 2023: guidance cut in half, credibility damaged

As COVID-era vaccine and treatment demand wound down, FY2023 revenue fell 41% year over year. The adjusted EPS guidance Pfizer had confidently set at the start of the year — $3.25-3.45 — was cut to $1.45-1.65 by the Q3 FY2023 call, a roughly 55% reduction; actual results landed at $1.84, barely clearing even that lowered bar. That same December, Pfizer closed its $43B acquisition of oncology company Seagen as a rebound bet, and opened FY2024 with what it called a "foundational year," guiding to a deliberately conservative $58.5-61.5B in revenue and $2.05-2.25 in adjusted EPS.

2024: a conservative target, beaten decisively

FY2024 came in well ahead of that cautious guidance — revenue reached $63.6B, above the top of the range, and adjusted EPS hit $3.11, 38% above the original top-end target. At the Q4 FY2024 call (February 2025), CEO Albert Bourla said 2024 "was a year of strong execution and results" and that the company had "met or exceeded our goals for each" strategic priority. Between the Seagen integration progressing, margins expanding, and $7.8B of debt paid down, management's tone on the earnings call reached its highest point in three years.

Spring 2025: two shocks, one month apart

Then, just three months later, two setbacks landed almost simultaneously. First, danuglipron — an oral obesity-drug candidate Pfizer had been counting on — was discontinued entirely after a safety signal emerged in trials. Then, on April 2, 2025, the Trump administration issued a tariff executive order, and the Q1 FY2025 earnings call that followed was dominated by tariff-related questions. Bourla used a phrase he hadn't used before — "the current volatile external environment" — and management's tone score on that call fell to a three-year low.

The response: buy the pipeline, and cut a deal with Washington

Pfizer's response split into two tracks. One was filling the pipeline gap through dealmaking — licensing a drug from China's 3SBio, and pursuing obesity-drug company Metsera, which triggered a bidding war after Novo Nordisk entered with a higher offer (Pfizer publicly called Novo's bid "illusory" and antitrust-violating, and ultimately won the deal). The other was direct negotiation with the government: in September 2025, Pfizer reached a "voluntary agreement" with the Trump administration to bring U.S. drug prices closer to other developed countries' levels, in exchange for a three-year exemption from Section 232 tariffs.

Guidance scorecard

FY2023's guidance was cut 55% within three quarters of the year starting, and results barely cleared even the reduced range. Whether the FY2024-FY2025 pattern of repeated beats reflects a genuine turnaround or a "guide low after losing credibility" habit isn't fully resolvable from this data alone. Source: Q3 FY2023, Q4 FY2023, Q4 FY2024, and Q3 FY2025 earnings calls; 10-K FY2025, p.44-45.

Timeline

• Oct 2023FY2023 adjusted EPS guidance cut roughly in half, from $3.25-3.45 to $1.45-1.65.
• Dec 2023Seagen acquisition completes ($43B) — Pfizer's largest-ever deal, debt-financed.
• Feb 2025Q4 FY2024 call: "met or exceeded our goals for each" priority — confidence at a three-year high.
• Apr 2025Oral obesity drug danuglipron discontinued after a safety signal.
• Apr 2, 2025Trump administration tariff executive order; the following earnings call is dominated by tariff questions.
• Sep-Nov 2025Metsera acquisition battle with Novo Nordisk, won by Pfizer; simultaneously, a voluntary drug-pricing and tariff agreement is reached with the Trump administration.
• Feb 2026Q4 FY2025 call: 2026 outlook is a recovery, but starts already carrying M&A dilution; the "pre-pandemic margin" phrase is no longer mentioned.

Our read

Pfizer's last three years trace a full cycle: a credibility-damaging guidance cut, a deliberately conservative comeback that overdelivered, and then two unrelated shocks landing in the same month that forced a shift toward both acquisitions and direct government negotiation. The operational recovery in FY2024-FY2025 looks real by the numbers, but the guidance pattern itself — cut hard once, then beat conservative targets twice in a row — leaves open whether management has simply gotten more cautious in how it sets expectations. That's worth watching in FY2026, the first year that has to absorb both the Metsera dilution and the new government pricing agreement at the same time.

What we still don't know

• How much Pfizer ultimately paid to win the Metsera bidding war, and whether the Novo Nordisk dispute is fully resolved requires data from the Q1 FY2026 call and later to confirm.
• The real reason the "return to pre-pandemic operating margins" goal stopped being mentioned (achieved quietly vs. quietly abandoned) can only be judged by whether the phrase resurfaces or a replacement goal is introduced in future calls.
• The final terms of the September 2025 government agreement aren't settled — the deal wasn't yet a "binding final agreement" as of the data reviewed here, so actual terms could still shift.